TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 24 hour urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean IGF-1 and GH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in urinary endocrine disrupting chemical levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in body composition (weight and visceral adipose tissue volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: displacement of the mesh one day after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: displacement of the mesh one week after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: displacement of the mesh six month after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative 24th hours pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative 6th months pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in carbon monoxide diffusing capacity (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Adverse Events (AEs) - Part 1
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Total Hemoglobin (Hb) Level from Baseline to End of 16-Week Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants with Adverse Events (AEs) - Part 2
Endpoint domain: Adverse events/effects
Primary endpoint: Sealing pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cost-effectiveness of care organization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence and Severity of Peripheral Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Acceptable Restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of participants with active pulmonary TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Treatment response by change of calculated cyst volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence during follow up
Endpoint domain: Mortality/survival
Primary endpoint: Changes from baseline negative dimension score of PANSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of plasma triglycerides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Ventricular Rate (VR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in RR Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in PR Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in QRS Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of viral infections
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: relapse (graft-versus-tumor effect)
Endpoint domain: Adverse events/effects
Primary endpoint: Pain response during Cold Pressor Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful blood extraction with one puncture attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in Symptom Burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Characterization of the microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Major Bleeding, Minor Bleeding, or Major Vascular Access Site Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Pediatric Anesthesia Emergence Delirium (PAED) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Indirect Calorimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment-emergent Serious AEs (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With TEAEs Leading to Death
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Hemoglobin Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Systolic and Diastolic Arterial Blood Pressure (BP) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lack of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Atrial Thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum anal resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rectal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diary card summary symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in serum sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety parameters (e.g., adverse events, vital signs, EGG, laboratory measurements)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of steady state PK parameters of NE and EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of steady state PK parameters of NE and EE in combination with trametinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of vaginal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acceptability of the eLSDA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of the eLSDA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amino acid intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood amino acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of significantly improved child outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of significantly improved maternal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics/pharmacodynamics (PK/PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal density measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor-to-background ratio of mean fluorescence intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Volleyball performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of periods of sick-leave, full-time or part-time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to progression to symptomatic multiple myeloma
Endpoint domain: Mortality/survival
Primary endpoint: Vaginal Delivery rates
Endpoint domain: Mortality/survival
Primary endpoint: Oswestry Low Back Pain Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of successful recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of any stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of study device-related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of emboli in new territory (ENT)
Endpoint domain: Adverse events/effects
Primary endpoint: CD4+ T cell decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to rebound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on immediate cued recall task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance on delayed cued recall task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perfect reperfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: thickness of epidermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Distant, local/regional, and ipsilateral breast relapse
Endpoint domain: Mortality/survival
Primary endpoint: First breast cancer recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Relapse-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Retinol binding protein, transferrin receptor, and C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catecholamine blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Exercise testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficult Tracheal Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: absolute bioavailability of iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative cardiac output ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Strength / Power Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Retention in Combination Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Participant-rated Acceptability of Combination Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Platelet function (shear stress dependent platelet adhesion and aggregation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Discharge ability time period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Positive Cores Associated With Disease Progression of Prostate Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alcohol Quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol-related Harm
Endpoint domain: Adverse events/effects
Primary endpoint: Alcohol Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Grade 4 Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Parasitological clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye movement velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupil area change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of occurrence of venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of occurrence of major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change in Severity of Alopecia Tool (SALT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evolution of the gradient Pmsf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the tested shampoo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Absolute Change in S-K
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral dynamics
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in prostate specific antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Absolute Relative Difference in Hypoglycemia Prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Relative Difference in Hypoglycemia Prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinical survival
Endpoint domain: Mortality/survival
Primary endpoint: Chronic Kidney Disease Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Days to revert ICUAW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sessions to revert ICUAW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lifestyle score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean number of melanocytes per high power field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of IL-1β production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: erythroid response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with recanalized portal vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: rate of spontaneous prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Maximum percent reduction in the longest diameter of the primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate of residual disease to Nexavar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum Copeptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of HepaStem
Endpoint domain: Adverse events/effects
Primary endpoint: neuropsych battery results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom rating scales results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: violent event
Endpoint domain: Adverse events/effects
Primary endpoint: Reflux Disease Questionnaire (RDQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pediatric Sinonasal Symptom Survey (SN-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Birth weight for gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Packing density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With a PEPI Score Equal to Zero
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of clinical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Achieved 5% Weight Loss Goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation coefficient between preoperative FLR-GC and post-operative ICG R15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median variation of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PBR Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median PBR Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent AEs at Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent AEs All Cycles
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Severe (i.e., CTCAE Grade ≥3) TEAEs Reported for ≥2% of Patients in Either Treatment Group and Overall Throughout the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Study-Drug-Related TEAEs Reported for ≥2% of Patients in Either Treatment Group Throughout the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Ten meter walk test (10MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Index for Spinal Cord Injury II (WISCI-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence Measures (FIM) gait score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clinico-radiologic response of primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flash Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of postoperative respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of t-VNS in schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of t-VNS in schizophrenia
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of salvage radiation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Headache Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving at Least a 50% Improvement in GERD-HRQL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe obesity-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selenium level in plasma and erythrocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: severe postoperative complications within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: reoperation for small bowel obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: systemic availability of diet-derived amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endoscopy insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in activity in specific brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive and hedonic perception
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent improvement in Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HbA1C Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vertebral structural endplate defect phenotype (Brayda-Bruno scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertebral structural endplate defect phenotype (Feng Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral ulcer activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School presence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Physical functioning as measured by the subscale physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Functional Capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the volume of thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TcPO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from Baseline in 28-day seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response rate at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specific patient-reported outcomes for arthroplasty
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: exercise capacity (maximal oxygen consumption: VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported victimisation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status